Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka
Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka soldits scanners in radiology and intraoperative markets and Corometricsmaintained exclusive U.S. sales and marketing rights to Alokascanners in the ob/gyn and veterinary markets. Both firms arebased in Wallingford, CT.
The new structure enables the two firms to be more responsiveto customers by allowing each to focus on its core area of expertise-- Aloka in ultrasound and Corometrics in monitoring products-- according to James Pietropaolo, vice president of sales andmarketing. Corometrics will continue to provide service for allAloka ultrasound products in the U.S.
In other Aloka news, the company has announced its MultiViewupgrade for the SSD-2000 ultrasound scanners. The upgrade improvesgray-scale and color Doppler performance and includes a PowerFlowDoppler feature. All SSD-2000 units in the field are upgradableto MultiView and Aloka in August shifted production to new SSD-2000MultiView scanners.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.